title: Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients.
abstract: OBJECTIVE
  To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI).
  
  
  METHODS
  Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration.
  
  
  RESULTS
  On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day.
  
  
  CONCLUSIONS
  CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic.
authors.forename: Nadezda
authors.initials: N
authors.lastname: Petejova
authors.forename: Arnost
authors.initials: A
authors.lastname: Martinek
authors.forename: Jana
authors.initials: J
authors.lastname: Zahalkova
authors.forename: Jana
authors.initials: J
authors.lastname: Duricova
authors.forename: Hana
authors.initials: H
authors.lastname: Brozmannova
authors.forename: Karel
authors.initials: K
authors.lastname: Urbanek
authors.forename: Milan
authors.initials: M
authors.lastname: Grundmann
authors.forename: Jiri
authors.initials: J
authors.lastname: Plasek
authors.forename: Ivana
authors.initials: I
authors.lastname: Kacirova
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000628:therapy*; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D016638:Critical Illness; D016903:Drug Monitoring; D005260:Female; D006440:Hemofiltration; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018805:Sepsis / Q000097:blood / Q000188:drug therapy*; D014640:Vancomycin / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin